Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya Therapeutics Inc. is based in HOUSTON.
| Revenue (Most Recent Fiscal Year) | $3.55M |
| Net Income (Most Recent Fiscal Year) | $-14.88M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.96 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4966.75% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -61.05% |
| Return on Assets (Trailing 12 Months) | -53.61% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.43 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.69 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.98 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 16.73M |
| Free Float | 14.72M |
| Market Capitalization | $112.22M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 0.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 39.75% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |